-
1
المؤلفون: Vincent J. Willey, Matthew J. Crowley
المصدر: Diabetes Care. 45:2808-2810
مصطلحات موضوعية: Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, Diabetes Mellitus, Internal Medicine, Humans, Disease Management
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a68dc687b4728dbbaf9976e7bcca2a
https://doi.org/10.2337/dci22-0030 -
2
المؤلفون: Rakesh Luthra, Effie Kuti, Chi Nguyen, Vincent J. Willey
المصدر: Current Medical Research and Opinion. 36:1927-1938
مصطلحات موضوعية: Male, medicine.medical_specialty, endocrine system diseases, Myocardial Infarction, Disease, Type 2 diabetes, 030204 cardiovascular system & hematology, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Health care, medicine, Humans, In patient, 030212 general & internal medicine, Intensive care medicine, Aged, Retrospective Studies, Heart Failure, Health economics, business.industry, Incidence, Health Care Costs, General Medicine, Middle Aged, Patient Acceptance of Health Care, medicine.disease, United States, Hospitalization, Stroke, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Ischemic Attack, Transient, Heart failure, Female, business, Risk assessment
الوصف: Description of risk of cardiovascular (CV) events associated with diabetes is evolving. This US-based real-world study estimated risk of future CV events and heart failure (HF) from type 2 diabetes (T2DM) only, prior CV events only or T2DM plus prior CV events, versus controls, and evaluated healthcare resource utilization (HCRU) and costs. This retrospective cohort study queried claims and mortality data for 638,301 patients: T2DM only (377,205); prior CV events only (130,964); both T2DM and prior CV events (130,132); and matched (1:1) controls, during 1 January 2012–31 December 2012. Cardiovascular diagnoses/events and death were assessed individually, and as composite endpoint (myocardial infarction [MI], stroke, transient ischemic attack [TIA], peripheral artery disease [PAD]), during follow-up, ending 31 July 2018. Adjusting for age and gender, patients with T2DM only were 1.6, prior CV events only 2.5 and T2DM plus prior CV events 3.8 times likelier to have primary composite CV events relative to controls, p In this large and geographically broad US based cohort, CV risk for T2DM patients was elevated, as was the risk for patients with prior CV events, while patients with T2DM plus prior CV events had the highest risk of future CV events. The substantial clinical and economic burden of CV events and HF in patients with both T2DM and prior CV events suggest a need for an integrated treatment and targeted intervention across both conditions.
-
3
المؤلفون: Todd Hobbs, Amit D. Raval, Jonathan Bouchard, Jay Visaria, David M. Kern, Neeraj N. Iyer, Vincent J. Willey, Sheldon X. Kong
المصدر: ClinicoEconomics and Outcomes Research: CEOR
مصطلحات موضوعية: Research design, microvascular complications, medicine.medical_specialty, Longitudinal study, endocrine system diseases, type 2 diabetes mellitus, Economics, Econometrics and Finance (miscellaneous), healthcare costs, 03 medical and health sciences, 0302 clinical medicine, macrovascular complications, Internal medicine, Diabetes mellitus, Health care, medicine, 030212 general & internal medicine, Macrovascular disease, Original Research, diabetes costs, diabetes, Vascular disease, business.industry, 030503 health policy & services, Health Policy, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, Retrospective cohort study, medicine.disease, ClinicoEconomics and Outcomes Research, 0305 other medical science, business
الوصف: Jay Visaria,1 Neeraj N Iyer,2 Amit D Raval,3 Sheldon X Kong,2 Todd Hobbs,2 Jonathan Bouchard,2 David M Kern,4 Vincent J Willey1 1HealthCore, Inc., Wilmington, DE, USA; 2Novo Nordisk, Inc., Plainsboro Township, NJ, USA; 3Merck & Co., Inc, Kenilworth, NJ, USA; 4Janssen Research and Development, Titusville, NJ, USACorrespondence: Jay VisariaHealthCore, Inc., 123 Justison Street, Suite 200, Wilmington, DE 19801, USATel +1 302 230-2117Email jvisaria@healthcore.comObjective: The objective of this study was to estimate the incremental long-term costs associated with T2DM attributable to vascular diseases.Research Design and Methods: This retrospective cohort study identified newly diagnosed (incident) T2DM patients in 2007 (baseline to 01/01/2006) using the HealthCore Integrated Research Database, a repository of nationally representative claims data. Incident T2DM patients were 1:1 exact matched on age, gender and other factors of interest to non-DM patients, and followed until the earlier of 8 follow-up years or death. Patients with documented vascular disease diagnosis were identified during the study period. All-cause and T2DM/vascular disease-related annual healthcare costs were examined for each follow-up year.Results: The study included 13,883 individuals with T2DM and matched non-DM controls. Among individuals with T2DM, 11,792 (85%) had vascular disease versus 9251 (66.6%) non-T2DM between 01/01/2006 and 12/31/2015. Among T2DM patients, mean all-cause annual costs were greater than in non-T2DM patients ($13,806 vs $7,243, baseline, $21,745 vs $8,524, post-index year 1, $12,756-$14,793 vs $8,349-$9,940 years 2– 8, p< 0.001), respectively. A similar trend was observed for T2DM/vascular disease-related costs (p< 0. 001). T2DM/vascular disease-related costs were largest during post-index year 1, accounting for the majority of all-cause cost difference between T2DM patients and matched non-DM controls. Incident T2DM individuals without vascular disease at any time had significantly lower costs compared to non-DM controls (p< 0. 001) between years 2– 8 of follow-up.Conclusion: Vascular disease increased the cost burden for individuals with T2DM. The cost impact of diabetes and vascular disease was highest in the year after diagnosis, and persisted for at least seven additional years, while the cost of T2DM patients without vascular disease trended lower than for matched non-DM patients. These data highlight potential costs that could be offset by earlier and more effective detection and management of T2DM aimed at reducing vascular disease burden.Keywords: type 2 diabetes mellitus, microvascular complications, macrovascular complications, diabetes, healthcare costs, diabetes costs
وصف الملف: text/html
-
4
المؤلفون: Abiy Agiro, Qinli Ma, Qian Shi, Lauren E. Parlett, Laura Herrera Scott, Vincent J. Willey, Geoffrey Crawford
المصدر: Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-3 (2021)
Diabetology & Metabolic Syndromeمصطلحات موضوعية: Pediatrics, medicine.medical_specialty, RC620-627, business.industry, Endocrinology, Diabetes and Metabolism, Type 2 Diabetes Mellitus, 030209 endocrinology & metabolism, Non alcoholic, Retrospective cohort study, 030204 cardiovascular system & hematology, medicine.disease, Healthcare utilization and cost, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Type 2 diabetes mellitus, Internal Medicine, medicine, Healthcare cost, Steatohepatitis, business, Nutritional diseases. Deficiency diseases, Letter to the Editor, Children, Non-alcoholic steatohepatitis
الوصف: This claims-based retrospective cohort study examined the prevalence and incremental impact of non-alcoholic steatohepatitis among children with type 2 diabetes mellitus in the United States. Although diagnoses of non-alcoholic steatohepatitis were not common among diabetic children, it was associated with significantly higher incremental healthcare cost and risk of hospitalization.
-
5
المؤلفون: Elizabeth L. Eby, Samuel B. Governor, Chi Nguyen, Felicia Gelsey, Jiat Ling Poon, Vincent J. Willey, Judith J. Stephenson
المصدر: Diabetes. 70
مصطلحات موضوعية: Endocrinology, Diabetes and Metabolism, Diabetes mellitus, Internal Medicine, medicine, Computational biology, Disease cluster, Psychology, medicine.disease
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c16b87573e7baf661b23bb65e2ba823e
https://doi.org/10.2337/db21-50-lb -
6
المؤلفون: Temitope Olufade, Siting Zhou, Mark J. Cziraky, David M. Kern, Ozgur Tunceli, Vincent J. Willey, Deborah Anzalone
المصدر: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
مصطلحات موضوعية: Time Factors, Epidemiology, 030204 cardiovascular system & hematology, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Cardiovascular Disease, 030212 general & internal medicine, guidelines, Practice Patterns, Physicians', Original Research, education.field_of_study, American Heart Association, Health Services, Treatment Outcome, Cardiovascular Diseases, Practice Guidelines as Topic, Cardiology, lipids (amino acids, peptides, and proteins), Guideline Adherence, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Statin, medicine.drug_class, Population, Specialty, Pharmacy, Risk Assessment, statins, lipids, 03 medical and health sciences, Diabetes mellitus, Internal medicine, medicine, Humans, education, Dyslipidemias, Retrospective Studies, Insurance, Health, Cholesterol, business.industry, American College of Cardiology/American Heart Association, cholesterol, Guideline, Protective Factors, medicine.disease, United States, chemistry, Observational study, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Biomarkers, Health Services and Outcomes Research
الوصف: Background The purpose of this study was to characterize changes in statin utilization patterns in patients newly initiated on therapy in the 2 years following the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol management guideline in a large US health plan population. Methods and Results This retrospective, observational study used administrative medical and pharmacy claims data to identify patients newly initiated on statin therapy over 4 quarters prior to and 8 quarters following the release of the guideline (average N/quarter=3596). Patients were divided into the 4 statin benefit groups ( SBG s) based on risk factors and laboratory lipid levels as defined in the guideline: SBG 1 (with atherosclerotic cardiovascular disease [ ASCVD ]; N=1046/quarter), SBG 2 (without ASCVD , with low‐density lipoprotein cholesterol ≥190 mg/dL; N=454/quarter), SBG 3 (without ASCVD , aged 40–75 years, with diabetes mellitus, low‐density lipoprotein cholesterol 70–189 mg/dL; N=1391/quarter), SBG 4 (no ASCVD or diabetes mellitus, age 40–75 years, low‐density lipoprotein cholesterol 70–189 mg/dL, estimated 10‐year ASCVD risk of ≥7.5%; N=705/quarter). Demographic variables, statin utilization patterns, lipid levels, and comorbidities were analyzed for pre‐ and postguideline periods. Postguideline, gradually increased high‐intensity statin initiation occurred in SBG 1, SBG 2, and in SBG 3 patients with 10‐year ASCVD risk ≥7.5%. Moderate‐ to high‐intensity statin initiation gradually increased among SBG 4 patients. Recommended‐intensity statin choice changed to a greater degree among patients treated by specialty care physicians. Regarding sex, target‐intensity statin initiation was lower in women in all groups before and after guideline release. Conclusions Prescriber implementation of the guideline recommendations has gradually increased, with the most marked change in the increased initiation of high‐intensity statins in patients with ASCVD and in those treated by a specialist.
-
7
المؤلفون: Ozgur Tunceli, Iftekhar Kalsekar, Amy Stanford, Suma Vupputuri, Vincent J. Willey, David M. Kern, Kelly F Bell, Bingcao Wu
المصدر: BMJ Open Diabetes Research & Care
مصطلحات موضوعية: medicine.medical_specialty, National Health and Nutrition Examination Survey, Endocrinology, Diabetes and Metabolism, Population, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Health Care Management, urologic and male genital diseases, Logistic regression, Kidney Failure, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Epidemiology, medicine, Epidemiology/Health Services Research, Intensive care medicine, education, education.field_of_study, Kidney Function Test, Kidney Disorder, business.industry, Type 2 Diabetes Mellitus, medicine.disease, female genital diseases and pregnancy complications, Kidney disorder, business, Kidney disease
الوصف: Objective To describe the estimated prevalence and temporal trends of chronic kidney disease (CKD) treatment patterns, and the association between CKD and potential factors for type 2 diabetes mellitus (T2DM) in different demographic subgroups. Research design and methods This was a cross-sectional analysis of adults with T2DM based on multiple US National Health and Nutrition Examination Survey (NHANES) datasets developed during 2007–2012. CKD severity was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines using the CKD Epidemiology Collaboration (CKD-EPI) equation: mild to moderate=stages 1–3a; moderate to kidney failure=stages 3b–5. Multivariable logistic regression analyses were performed to assess the associations between CKD and potential factors. Results Of the adult individuals with T2DM (n=2006), age-adjusted CKD prevalence was 38.3% during 2007–2012; 77.5% were mild-to-moderate CKD. The overall age-adjusted prevalence of CKD was 40.2% in 2007–2008, 36.9% in 2009–2010, and 37.6% in 2011–2012. The prevalence of CKD in T2DM was 58.7% in patients aged ≥65 years, 25.7% in patients aged
-
8
المؤلفون: J.M. Kozuch, K.H. Willey, Vincent J. Willey, Jennifer A Reinhold, S.M. Amin, B.L. Kelly, E.A. Kim
المصدر: Value in Health. 14(3)
مصطلحات موضوعية: Medical home, medicine.medical_specialty, Nursing, business.industry, Diabetes mellitus, Family medicine, Health Policy, medicine, Public Health, Environmental and Occupational Health, medicine.disease, business, Pharmacist intervention
-
9
المؤلفون: Charles P. Quesenberry, Susan A. Oliveria, Robert D. McQuade, Ai-Lin Tsai, John W. Newcomer, Marianne Ulcickas Yood, Gerald N. DeLorenze, Vincent J. Willey, Gilbert L'Italien
المصدر: Pharmacoepidemiology and drug safety. 18(9)
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Diabetes risk, Epidemiology, medicine.drug_class, medicine.medical_treatment, Aripiprazole, Atypical antipsychotic, Quinolones, Piperazines, Cohort Studies, Benzodiazepines, Internal medicine, medicine, Diabetes Mellitus, Humans, Pharmacology (medical), Ziprasidone, Antipsychotic, Psychiatry, Clozapine, Retrospective Studies, business.industry, Mental Disorders, Retrospective cohort study, Middle Aged, United States, Thiazoles, Olanzapine, Cohort, Quetiapine, Female, business, medicine.drug, Antipsychotic Agents
الوصف: Purpose The purpose of this study was to examine the association between atypical antipsychotics, including the newer agents, aripiprazole and ziprasidone, and newly treated diabetes, using the largest post-marketing cohort of patients exposed to these newer treatments that has been studied to date. Methods Identified two overlapping cohorts—a simple cohort (all antipsychotic users) and an inception cohort (new users of antipsychotics)—using automated data from three United States sites (60.4 million covered lives). Patients exposed to antipsychotics ≥ 45 days were identified and followed for incident diagnoses of treated diabetes. Data analysis accounted for drug switching and non-consistent drug use. Results In the 55 287-member inception cohort, 357 cases of newly treated diabetes were identified. Compared with current use of typical antipsychotics, current users of aripiprazole (adjusted hazard ratio (aHR) 0.93, 95% confidence interval (CI) 0.50–1.76), quetiapine (aHR 1.04, 95%CI, 0.67–1.62), risperidone (aHR 0.85, 95%CI, 0.54–1.36) and ziprasidone (aHR 1.05, 95%CI, 0.54–2.08) had similar low risk of diabetes. Patients exposed to olanzapine had an increased risk of diabetes (aHR 1.71, 95%CI, 1.12–2.61), and although the effect estimate is imprecise, clozapine-exposed patients had a trend towards an elevated hazard ratio (aHR 2.58, 95%CI, 0.76–8.80). Results for the simple cohort were similar. Conclusions Relative to typical antipsychotics, aripiprazole, ziprasidone, risperidone and quetiapine were not associated with an increased risk of diabetes; olanzapine and clozapine were associated with an increased risk. This analysis constitutes the largest post-marketing pharmacoepidemiologic study to date that includes the newer agents. Copyright © 2009 John Wiley & Sons, Ltd.
-
10
المؤلفون: Michael F. Bullano, Laura Menditto, Vincent J. Willey, W. Daniel Grochulski, Maxine D. Fisher
المصدر: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 63(24)
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Insulin Glargine, Hypoglycemia, Insurance Claim Review, Diabetes mellitus, Internal medicine, Medicine, Humans, Hypoglycemic Agents, Insulin, Aged, Retrospective Studies, Pharmacology, Glycated Hemoglobin, business.industry, Insulin glargine, Health Policy, Type 2 Diabetes Mellitus, Middle Aged, medicine.disease, Confidence interval, Insulin, Long-Acting, Endocrinology, Diabetes Mellitus, Type 2, Cohort, Number needed to treat, Female, business, medicine.drug
الوصف: Purpose. Rates of hypoglycemic events and their associated costs were compared among patients with type 2 diabetes mellitus newly initiated on insulin glargine or a premixed insulin fixed-combination product. Methods. Patients newly initiated on insulin glargine or premixed insulin fixed-combination products (including pen delivery systems) between June 1, 2001, and February 29, 2004, were identified using an administrative claims database. Hypoglycemic events were identified from International Classification of Diseases, 9th Revision, Clinical Modification codes. Multivariate analyses were performed. Results. A total of 2315 patients met the inclusion criteria. Of those, 1212 received insulin glargine and 1103 received a premixed fixed-combination insulin product. The mean ± S.D. treatment duration was 13.7 ± 8.1 months. Patients treated with premixed insulin had a higher hypoglycemic event rate than glargine patients (13.8 versus 7.0/100 patients/year; p = 0.027), which yielded a number needed to treat of 15 patients. The mean cost per hypoglycemic event was $1049 (95% confidence interval, $426–1672). The mean annual cost of all insulin use was $46 more for the insulin glargine cohort than for those who received premixed insulin ($534 versus $488, respectively) ( p < 0.05). Mean postindex insulin use was higher in patients receiving premixed insulin than in those treated with insulin glargine (48.1 versus 43.8 units per day) ( p < 0.05). Conclusion. Patients with type 2 diabetes mellitus who were newly initiated on insulin glargine had a lower rate of hypoglycemic events compared with patients newly initiated on a premixed fixed-combination insulin product. Treatment of 15 patients with insulin glargine instead of premixed insulin for one year would avoid one hypoglycemic event per year.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::171190db6617dc8e9e546d90afe6c966
https://pubmed.ncbi.nlm.nih.gov/17158695
إعادة تعيين المنقحات
عرض المنقحات (%%عد%%)
PDF full text from Publisher 
Find this article in full text from Springer Verlag. 
Full Text via ClinicalKey